论文部分内容阅读
[目的]研究新型血清标志物Monototal在非小细胞肺癌诊断中的临床应用价值。[方法]选取197例非小细胞肺癌患者、35例肺部良性疾病患者和120例健康体检血清标本,检测CA125、CEA、CYFRA21-1、SCC和Monototal水平。采用SPSS 19.0进行统计分析,比较不同血清肿瘤标志物诊断非小细胞肺癌的敏感度和特异性。[结果]非小细胞肺癌组血清Monototal中位浓度是53.19U/L,显著性高于肺部良性组(41.60U/L)和健康体检组(5.55U/L)(P均<0.01)。血清Monototal诊断非小细胞肺癌的敏感度(30.46%)和特异性(91.43%)与Cyfra21-l(38.07%,94.29%)较为接近。不同临床分期中,Monototal诊断Ⅰ期肺癌的敏感度最高,为19.05%,Cyfra21-1则为17.86%。Cyfra21-1诊断Ⅱ、Ⅲ、Ⅳ期肺癌的敏感度最高,分别为46.51%、61.90%和75.00%;而Monototal则分别为30.23%、50.00%和41.67%。[结论 ]Monototal是一种较好的非小细胞肺癌肿瘤标志物,对非小细胞肺癌的诊断效能接近Cyfra21-1,对早期非小细胞肺癌辅助诊断可能有更好的诊断价值。
[Objective] To study the clinical value of Monototal, a new serum marker in the diagnosis of non-small cell lung cancer. [Methods] The serum levels of CA125, CEA, CYFRA21-1, SCC and Monototal were detected in 197 patients with NSCLC, 35 patients with benign pulmonary disease and 120 healthy people. SPSS 19.0 was used for statistical analysis to compare the sensitivity and specificity of different serum tumor markers in the diagnosis of non-small cell lung cancer. [Results] The median Monototal concentration in non-small cell lung cancer was 53.19U / L, which was significantly higher than that in benign lung (41.60U / L) and healthy subjects (5.55U / L) (P <0.01). Sensitivity (30.46%) and specificity (91.43%) of serum Monototal in diagnosing non-small cell lung cancer were similar to those of Cyfra21-1 (38.07%, 94.29%). Among different clinical stages, Monototal had the highest sensitivity for stage I lung cancer with 19.05% and Cyfra21-1 with 17.86%. Cyfra21-1 had the highest sensitivity in diagnosing stage II, III and IV lung cancer, which was 46.51%, 61.90% and 75.00% respectively; while Monototal was 30.23%, 50.00% and 41.67% respectively. [Conclusion] Monototal is a good tumor marker of non-small cell lung cancer. Its diagnostic value for non-small cell lung cancer is close to that of Cyfra21-1, which may be of great value in the diagnosis of early non-small cell lung cancer.